Prostate‐specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer
暂无分享,去创建一个
N. Lawrentschuk | D. Murphy | M. Hofman | D. Moon | P. Jenjitranant | B. Kelly | J. O'Brien | J. Buteau | Aoife McVey | Veeru Kasivisvanithan | Renu Eapen
[1] D. Bolton,et al. Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer , 2022, Prostate Cancer and Prostatic Diseases.
[2] M. Ng,et al. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[3] N. Lawrentschuk,et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. , 2020, European urology.
[4] N. Lawrentschuk,et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.
[5] G. Pond,et al. A Prospective , Multi-site , International Comparison of F-18 fluoro-methyl-choline , multi-parametric magnetic resonance and Ga-68 HBED-CC ( PSMA-11 ) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy : Clinical Performance and Patient Outcomes , 2019 .
[6] Gerard J Fitzsimmons,et al. From the Australian Institute of Health and Welfare , 2014, Communicable diseases intelligence quarterly report.